Literature DB >> 1905722

Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog.

P Lollar1, E T Parker.   

Abstract

The stability of activated human and porcine factor VIII (fVIII) differ, but a direct comparison of their structural and functional properties has not been made. Highly purified, heterodimeric human recombinant and porcine plasma-derived fVIII were exchanged into a common buffer and some minor contaminants were removed by anion-exchange chromatography. The activations of human and porcine fVIII by thrombin were studied by a two-stage coagulation assay using human citrated plasma as the standard. The peak activation of porcine fVIII was 10-fold greater than human fVIII (1.1 x 10(6) unit/mg versus 1.1 x 10(5) unit/mg). The proteolytic fragmentation of fVIII by thrombin was evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and was not different between human and porcine fVIII, yielding previously identified bands corresponding to fragments A1, A2, A3-C1-C2, and the B domain. Following activation by thrombin, human fVIII was subjected to cation-exchange (Mono S) high performance liquid chromatography at pH 6.0 under conditions that yields stable, heterotrimeric (A1/A2/A3-C1-C2) porcine fVIIIaIIa (Lollar, P., and Parker, C.G. (1990) Biochemistry 28, 666-674). Coagulant activity was recovered in a single peak that was less than 0.5% that of porcine fVIIIaIIa (1.2 x 10(4) unit/mg versus 2.6 x 10(6) unit/mg). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the peak fraction revealed bands corresponding to the A3-C1-C2 and A1 fragments but only trace levels of the A2 fragment. In contrast, activation of human fVIII by thrombin followed by Mono S HPLC at pH 5.0 produced a peak with 10-fold greater activity (1.2 x 10(5) unit/mg) than at pH 6.0 and which contained significant amounts of the A2 fragment. We conclude that human fVIIIIIa, like porcine fVIIIIIa, is a heterotrimer and propose that its apparent decreased coagulant activity is due to weaker association of the A2 subunit.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1905722

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.

Authors:  Thomas J Cramer; John H Griffin; Andrew J Gale
Journal:  Pathophysiol Haemost Thromb       Date:  2010-05-22

2.  Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation.

Authors:  Ernest T Parker; Pete Lollar
Journal:  Biochemistry       Date:  2007-08-04       Impact factor: 3.162

3.  A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX.

Authors:  Esther Bloem; Henriet Meems; Maartje van den Biggelaar; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2013-07-24       Impact factor: 5.157

4.  Identification of residues in the 558-loop of factor VIIIa A2 subunit that interact with factor IXa.

Authors:  Indu Jagannathan; H Travis Ichikawa; Tricia Kruger; Philip J Fay
Journal:  J Biol Chem       Date:  2009-09-28       Impact factor: 5.157

5.  Dissimilar interaction of factor VIII with endothelial cells and lipid vesicles during factor X activation.

Authors:  H J Brinkman; P Koster; K Mertens; J A van Mourik
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

6.  Modification of interdomain interfaces within the A3C1C2 subunit of factor VIII affects its stability and activity.

Authors:  Hironao Wakabayashi; Philip J Fay
Journal:  Biochemistry       Date:  2013-05-21       Impact factor: 3.162

7.  Mass spectrometry-assisted study reveals that lysine residues 1967 and 1968 have opposite contribution to stability of activated factor VIII.

Authors:  Esther Bloem; Henriet Meems; Maartje van den Biggelaar; Carmen van der Zwaan; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2012-01-03       Impact factor: 5.157

8.  Inhibition of human factor VIIIa by anti-A2 subunit antibodies.

Authors:  P Lollar; E T Parker; J E Curtis; S L Helgerson; L W Hoyer; M E Scott; D Scandella
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

9.  Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study.

Authors:  Divi Venkateswarlu
Journal:  BMC Struct Biol       Date:  2010-02-25

Review 10.  The molecular basis of factor V and VIII procofactor activation.

Authors:  R M Camire; M H A Bos
Journal:  J Thromb Haemost       Date:  2009-09-18       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.